Shareholder Soros Fund Management LLC Decreased Valeant Pharmaceuticals Intl (Put) (VRX) Stake

April 14, 2018 - By Heather Owens

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Corporate LogoBig Money Sentiment decreased to 0.97 in 2017 Q4. It has change of 0.02, from 2017Q3’s 0.99. The ratio dived due to VRX positioning: 51 sold and 74 reduced. 54 funds bought holdings and 67 increased holdings. Investors holded 169.87 million in 2017Q3 but now own 169.66 million shares or 0.12% less. Pinebridge Investments LP owns 3,854 shs. Bridgecreek Invest Ltd Liability Co holds 1.77% or 362,275 shs in its capital. Stifel Fin stated it has 218,123 shs. Cibc Ww Mkts Incorporated has 0.32% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 3.42M shs. Continental Advisors Limited Liability Company reported 0.69% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Quantbot Technology Ltd Partnership owns 43,455 shs. Advsr Preferred Llc has 1,487 shs for 0.01% of their capital. Blair William & Company Il reported 131,941 shs or 0.02% of all its holdings. Manufacturers Life Insur The has 1.23 million shs. Diamond Hill Cap Incorporated reported 34,500 shs. Moreover, Cibc Asset Mngmt Inc has 0.02% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 124,559 shs. Baystate Wealth Mngmt reported 149 shs. Alliancebernstein L P, New York-based fund reported 226,958 shs. Tocqueville Asset LP holds 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) or 22,091 shs. Toth Fincl Advisory accumulated 0% or 1,000 shs.

VRX had 0 selling transactions and 3 insider buys since March 8, 2018. This’s net activity of $876,370. $153,400 worth of stock was bought by DE SCHUTTER RICHARD U on Thursday, March 8. 15,000 shs were bought by Herendeen Paul, worth $241,470 on Tuesday, March 13.

The holdings In Valeant Pharmaceuticals Intl (Put) (VRX) was decreased owned by George Soros. According to 2017Q4 SEC form the decrease is 30.56%. By selling 660,000 shares Soros Fund Management Llc made the stock sank with 28.77%. The hedge fund run by George Soros is holding 1.50M shares, compared to the 2.16M from the previous quarter. And the reported value of the health care company is $31.17M for the 2017Q4. Valeant Pharmaceuticals Intl (Put) has $5.98B market cap. The stock increased 3.13% or $0.52 during the last trading session, reaching $17.15.Valeant Pharmaceuticals International, Inc. has volume of 10.80M shares. Since April 14, 2017 VRX has risen 42.00% and is uptrending. The stock outperformed the S&P500 by 30.45%.

Soros Fund Management Llc operates about $4.37 billion US Long portfolio. It rose its stake in Solaredge Technologies Inc by 314,488 shares to 1.01M shares, valued at $37.92M in 2017Q4, according to the filing. For a total of 269,632 shares it increased its holding in Lam Research Corp (NASDAQ:LRCX) by 158,207 shares in the quarter, and has risen its stake in Cbs Corp New (NYSE:CBS).

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8. They expect $0.66 earnings per share, down 76.43 % or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.25M for 6.50 P/E if the $0.66 EPS becomes a reality. After $0.98 actual earnings per share reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65 % negative EPS growth.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

In total 15 analysts cover Valeant Pharma (NYSE:VRX). “Buy” rating has 3, “Sell” are 4, while 8 are “Hold”. 20% are bullish. With $25.0 highest and $7.0 lowest [Target] Valeant Pharma has $16.27 average [Target] or -5.13% below the current ($17.15) price. 30 are the (NYSE:VRX)’s analyst reports since October 16, 2017 according to StockzIntelligence Inc. On Friday, December 15 the firm has “Underperform” rating given by Mizuho. On Wednesday, February 28 Cantor Fitzgerald maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with “Buy” rating. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Friday, January 19. On Monday, November 6 the company was maintained by Canaccord Genuity. On Thursday, March 15 the stock has “Hold” rating by H.C. Wainwright. On Monday, March 5 Deutsche Bank upgraded Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to “Buy” rating. On Tuesday, November 7 the firm has “Buy” rating given by Cantor Fitzgerald. On Tuesday, November 7 the firm earned “Sell” rating by Mizuho. On Friday, November 3 the stock has “Hold” rating by TD Securities. The stock rating was maintained by H.C. Wainwright with “Hold” on Thursday, November 9.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.